# CJC-1295 Ipamorelin: The GHRH + GHRP Synergy Stack, Cited > CJC-1295 Ipamorelin is a research combination of a long-acting GHRH analogue and a selective ghrelin-receptor GHRP. The dual-receptor synergy, the GH and IGF-1 numbers, and the open questions — every claim cited. Two receptors. Two pathways. One amplified GH pulse — larger than the sum. Here is what the literature actually measured, and where it goes quiet. ## TL;DR **CJC-1295 Ipamorelin** is two lab peptides used together. CJC-1295 is a long-acting copy of GHRH (the natural hormone that tells the pituitary gland to release growth hormone). Ipamorelin is a GHRP (a peptide that hits a second switch on the same gland — the ghrelin receptor). Each one alone raises growth hormone (GH). Fired together, they push a bigger GH pulse than either does on its own — the studies call this "synergy" (a combined effect larger than the two added up). In healthy adults, a single CJC-1295 dose raised GH 2- to 10-fold for six days or more [1]. The combination's downstream story — better sleep, faster recovery, slow body-composition change — is partly measured in single peptides and partly extrapolated. Neither peptide is FDA-approved, and the fixed blend has never been tested in a controlled trial. What people report — including the downsides — is on [the effects page](/effects). ## Cjc ipamorelin The pairing is built on a thirty-year-old finding. In normal men, a submaximal GHRP dose combined with GHRH stimulated GH release synergistically — the two acting through independent mechanisms [3]. That is the entire rationale in one sentence: two doors into the same room, opened at once, let more through than the sum of each opened alone. CJC-1295 works the GHRH door. It binds the GHRH receptor on the pituitary's GH-making cells (somatotrophs), raising cAMP and driving GH synthesis and release [5]. Ipamorelin works the ghrelin door. It binds GHS-R1a (the ghrelin receptor) on the same cells, raising intracellular calcium [2]. At the receptor level, co-activating both produced roughly twice the cAMP signal of the GHRH receptor alone [4]. Different switches, one output, amplified. ## The numbers that anchor the stack Most of the hard data is single-component. Treat it as the floor, not the blend. - **CJC-1295 (with DAC):** one subcutaneous dose raised mean plasma GH 2- to 10-fold for 6+ days and IGF-1 1.5- to 3-fold for 9–11 days in healthy adults; after multiple doses IGF-1 stayed above baseline up to 28 days [1]. - **Ipamorelin:** the first *selective* GH secretagogue — it released GH as well as older GHRPs but did not raise ACTH or cortisol above GHRH-stimulated levels even at doses over 200× the dose needed for GH release [2]. That selectivity is its signature. - **The synergy:** demonstrated in humans for a GHRP + GHRH pairing [3] and at the receptor level in transfected cells [4]. The [cjc 1295 dac](/cjc-1295-dac) form and the no-DAC [mod grf 1-29](/mod-grf-1-29) form sit on very different timescales — that distinction is its own page each. ## What it does not say Read the gap as carefully as the data. There is **no** peer-reviewed human pharmacology study of the pre-mixed CJC-1295 + ipamorelin combination itself. Every combination claim rests on (a) each peptide's own literature and (b) general GHRH+GHRP synergy work done with *related* peptides — not this exact pair [3][4]. The combination has never been tested as a fixed blend in a controlled clinical trial. Neither component is FDA-approved for any human use [6]. Both are WADA-prohibited at all times under Section S2. The stack raises GH and IGF-1 — that much is cited; downstream muscle gain and fat loss in humans are extrapolated, not established. This site is [CJC-1295 Ipamorelin research](/research), logged to source. It sells nothing. --- Two receptors logged on one onyx panel — the supra-additive GH crest read off single-peptide data and the general synergy work, the fixed blend's missing trial left as an empty cell; no clinic behind the console and nothing here dosed, stacked, or sold.